Patent: 10,500,287

Summary for Patent: 10,500,287

Title:	Amphipathic peptide
Abstract:	The present invention is directed to an amphipathic peptide and methods of using the amphipathic peptide for delivering small molecule agents to a cell. Ideally, the amphipathic cell penetrating peptide comprises less than approximately 50 amino acid residues with at least 6 arginine residues, at least 12 Alanine Residues, at least 6 leucine residues, optionally at least one cysteine residue, and at least two but no greater than three glutamic acids wherein the arginine residues are evenly distributed along the length of the peptide; and the peptide has a defined ratio of arginine to negatively charged amino acid residues and a defined ratio of hydrophilic amino acid residues to hydrophobic amino acid residues. The present invention is also directed to a nanoparticle and cell delivery system comprising the amphipathic cell penetrating peptide of the invention. The peptide, nanoparticle or cell delivery system of the invention may be used in therapy. For example, the peptide may be used as a therapeutic agent delivery system, in which the therapeutic agent may include nucleic acids or other small molecules.
Inventor(s):	Helen McCarthy, Aleksey Zholobenko, Ashley Davison, Tracy Robson
Assignee:	Phion Therapeutics Ltd
Application Number:	US16/215,183
Patent Claims:	see list of patent claims

Details for Patent 10,500,287

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338	February 02, 2010		2038-12-10
Glaxosmithkline Biologicals	AREXVY	respiratory syncytial virus vaccine, adjuvanted	For Injection	125775	May 03, 2023		2038-12-10

International Patent Family for US Patent 10,500,287

Country	Patent Number	Estimated Expiration
Denmark	2928909
Denmark	3415525
European Patent Office	2928909